Business Context and Reporting Period
This Form 8-K filing by X4 Pharmaceuticals, Inc. (a Delaware corporation and emerging growth company) reports a corporate governance event dated March 29, 2019. The filing details the election of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and associated compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the election of Murray W. Stewart, M.D., to the Board of Directors as a Class III director. His term continues until the 2020 annual meeting of stockholders. No financial material changes were reported in this document.
Guidance, Outlook, and Compensation Details
Management commentary is limited to the background of the new director and the terms of his appointment. Dr. Stewart brings extensive biopharmaceutical leadership experience, including prior roles as Chief Medical Officer at Rhythm Pharmaceuticals, Inc., and various leadership positions at GlaxoSmithKline (GSK).
Compensatory Arrangements:
- Initial Grant: A non-qualified stock option to purchase 6,854 shares of common stock at an exercise price of $17.41 per share (closing price on grant date).
- Annual Cash Fees: $35,000 per year for Board service.
- Annual Equity Grant: Eligible for a non-qualified stock option to purchase 3,427 shares annually on the date of the annual meeting, subject to serving on the Board for at least six months.
- Indemnification: Dr. Stewart has entered into the Company's standard form of indemnification agreement.
Committee assignments for Dr. Stewart have not yet been determined and will be disclosed in a future amendment.
Investor Verification Checklist
- Verify the stock price of $17.41 on March 29, 2019, to confirm the exercise price of the initial option grant.
- Review the Company's Director Compensation Policy to confirm the standard terms for cash fees and annual equity grants.
- Monitor future filings for the announcement of Dr. Stewart's specific committee assignments.
- Confirm the absence of any undisclosed transactions or understandings between Dr. Stewart and the Company as stated in the filing.